Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE)

被引:81
作者
Blauvelt, Andrew [1 ]
Guttman-Yassky, Emma [2 ,3 ]
Paller, Amy S. [4 ,5 ]
Simpson, Eric L. [6 ]
Cork, Michael J. [7 ,8 ]
Weisman, Jamie [9 ]
Browning, John [10 ]
Soong, Weily [11 ]
Sun, Xian [12 ]
Chen, Zhen [12 ]
Kosloski, Matthew P. [12 ]
Kamal, Mohamed A. [12 ]
Delevry, Dimittri [12 ]
Chuang, Chien-Chia [13 ]
O'Malley, John T. [13 ]
Bansal, Ashish [12 ]
机构
[1] Oregon Med Res Ctr, Portland, OR USA
[2] Icahn Sch Med Mt Sinai, Med Ctr, New York, NY 10029 USA
[3] Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA
[4] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
[5] Ann & Robert H Lurie Childrens Hosp, Chicago, IL USA
[6] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[7] Univ Sheffield, Sheffield Dermatol Res, Sheffield, S Yorkshire, England
[8] Sheffield Childrens Hosp, Clin Res Facil, Sheffield, S Yorkshire, England
[9] Adv Med Res PC, Atlanta, GA USA
[10] Univ Texas Hlth San Antonio, San Antonio, TX USA
[11] Alabama Allergy & Asthma Ctr AllerVie Hlth, Birmingham, AL USA
[12] Regeneron Pharmaceut Inc, 77 Old Saw Mill River Rd, Tarrytown, NY 10591 USA
[13] Sanofi, Cambridge, MA USA
关键词
ECZEMA; CHILDREN; HUMANIZATION; PREVALENCE; GUIDELINES; MANAGEMENT; PLACEBO; ADULTS;
D O I
10.1007/s40257-022-00683-2
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background For adolescent patients (aged >= 12 to <18 years) with uncontrolled moderate-to-severe atopic dermatitis (AD), 16 weeks of treatment with dupilumab resulted in substantial clinical benefit compared with placebo, with an acceptable safety profile. However, long-term data on the approved dose regimens of dupilumab in adolescents with AD are lacking. Objectives This open-label extension study (LIBERTY AD PED-OLE, NCT02612454) reports the long-term safety, efficacy, and pharmacokinetics of dupilumab in adolescents with moderate-to-severe AD who had participated in dupilumab parent trials. Methods Patients enrolled under the original study protocol received subcutaneous dupilumab according to a weight-based regimen (2 or 4 mg/kg every week). Following protocol amendment, patients were switched to subcutaneous dupilumab 300 mg every 4 weeks (q4w) irrespective of weight, and newly enrolled patients were started on dupilumab 300 mg q4w. Patients with an inadequate clinical response (Investigator's Global Assessment [IGA] score of 0/1 was not reached) to the q4w regimen could be uptitrated to the approved dupilumab dose regimens of 200 or 300 mg every 2 weeks (body weight <60 or >= 60 kg, respectively). Patients whose IGA score of 0/1 was maintained continuously for a 12-week period after week 40 were discontinued from dupilumab, monitored for relapse, and re-initiated on dupilumab if required. Results Data for 294 patients (mean age 14.7 years) were analyzed, 102 (34.7%) of whom had completed the 52-week visit at the database lock. The dupilumab long-term safety profile was comparable to that seen in adults and consistent with the known safety profile. Most treatment-emergent adverse events were mild/moderate. By week 52, 42.7% of patients had an IGA score of 0/1 (clear/almost clear), and 93.1%, 81.2%, and 56.4%, respectively, had at least a 50%, 75%, or 90% improvement in Eczema Area and Severity Index (EASI). Most (70.9%) patients required uptitration to the approved dupilumab dose regimen. The proportions of uptitrated patients with an IGA score of 0/1 or 75% improvement in EASI increased over time, reaching 35.7% and 51.9%, respectively, 48 weeks after the first uptitration visit. By week 52, 29.4% of patients had clear/almost clear skin sustained for 12 weeks and had stopped medication; 56.7% relapsed and were subsequently re-initiated on treatment, with a mean time to re-initiation of 17.5 (+/- standard deviation 17.3) weeks. Conclusions Consistent with results seen with short-term treatment, long-term treatment with dupilumab showed an acceptable safety profile while providing incremental clinical benefit with continued treatment over time. The high proportion of patients who needed uptitration because of inadequate response to q4w dosing supports the q2w dose regimen as optimal for this age group. Finally, the majority of patients who stopped medication after having clear/almost clear skin sustained over 12 weeks experienced disease recurrence, suggesting the need for continued dupilumab dosing to maintain efficacy.
引用
收藏
页码:365 / 383
页数:19
相关论文
共 31 条
[1]   Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis A Randomized Clinical Trial [J].
Bachert, Claus ;
Mannent, Leda ;
Naclerio, Robert M. ;
Mullol, Joaquim ;
Ferguson, Berrylin J. ;
Gevaert, Philippe ;
Hellings, Peter ;
Jiao, Lixia ;
Wang, Lin ;
Evans, Robert R. ;
Pirozzi, Gianluca ;
Graham, Neil M. ;
Swanson, Brian ;
Hamilton, Jennifer D. ;
Radin, Allen ;
Gandhi, Namita A. ;
Stahl, Neil ;
Yancopoulos, George D. ;
Sutherland, E. Rand .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 315 (05) :469-479
[2]   Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis [J].
Beck, Lisa A. ;
Thaci, Diamant ;
Hamilton, Jennifer D. ;
Graham, Neil M. ;
Bieber, Thomas ;
Rocklin, Ross ;
Ming, Jeffrey E. ;
Ren, Haobo ;
Kao, Richard ;
Simpson, Eric ;
Ardeleanu, Marius ;
Weinstein, Steven P. ;
Pirozzi, Gianluca ;
Guttman-Yassky, Emma ;
Suarez-Farinas, Mayte ;
Hager, Melissa D. ;
Stahl, Neil ;
Yancopoulos, George D. ;
Radin, Allen R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (02) :130-139
[3]   Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial [J].
Blauvelt, Andrew ;
de Bruin-Weller, Marjolein ;
Gooderham, Melinda ;
Cather, Jennifer C. ;
Weisman, Jamie ;
Pariser, David ;
Simpson, Eric L. ;
Papp, Kim A. ;
Hong, H. Chih-Ho ;
Rubel, Diana ;
Foley, Peter ;
Prens, Errol ;
Griffiths, Christopher E. M. ;
Etoh, Takafumi ;
Pinto, Pedro Herranz ;
Pujol, Ramon M. ;
Szepietowski, Jacek C. ;
Ettler, Karel ;
Kemeny, Lajos ;
Zhu, Xiaoping ;
Akinlade, Bolanle ;
Hultsch, Thomas ;
Mastey, Vera ;
Gadkari, Abhijit ;
Eckert, Laurent ;
Amin, Nikhil ;
Graham, Neil M. H. ;
Pirozzi, Gianluca ;
Stahl, Neil ;
Yancopoulos, George D. ;
Shumel, Brad .
LANCET, 2017, 389 (10086) :2287-2303
[4]   Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma [J].
Castro, M. ;
Corren, J. ;
Pavord, I. D. ;
Maspero, J. ;
Wenzel, S. ;
Rabe, K. F. ;
Busse, W. W. ;
Ford, L. ;
Sher, L. ;
FitzGerald, J. M. ;
Katelaris, C. ;
Tohda, Y. ;
Zhang, B. ;
Staudinger, H. ;
Pirozzi, G. ;
Amin, N. ;
Ruddy, M. ;
Akinlade, B. ;
Khan, A. ;
Chao, J. ;
Martincova, R. ;
Graham, N. M. H. ;
Hamilton, J. D. ;
Swanson, B. N. ;
Stahl, N. ;
Yancopoulos, G. D. ;
Teper, A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (26) :2486-2496
[5]  
ClinicalTrials.gov, STUD DUP AUT DEV US
[6]   Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension [J].
Cork, M. J. ;
Thaci, D. ;
Eichenfield, L. F. ;
Arkwright, P. D. ;
Hultsch, T. ;
Davis, J. D. ;
Zhang, Y. ;
Zhu, X. ;
Chen, Z. ;
Li, M. ;
Ardeleanu, M. ;
Teper, A. ;
Akinlade, B. ;
Gadkari, A. ;
Eckert, L. ;
Kamal, M. A. ;
Ruddy, M. ;
Graham, N. M. H. ;
Pirozzi, G. ;
Stahl, N. ;
DiCioccio, A. T. ;
Bansal, A. .
BRITISH JOURNAL OF DERMATOLOGY, 2020, 182 (01) :85-96
[7]   Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFE) [J].
de Bruin-Weller, M. ;
Thaci, D. ;
Smith, C. H. ;
Reich, K. ;
Cork, M. J. ;
Radin, A. ;
Zhang, Q. ;
Akinlade, B. ;
Gadkari, A. ;
Eckert, L. ;
Hultsch, T. ;
Chen, Z. ;
Pirozzi, G. ;
Graham, N. M. H. ;
Shumel, B. .
BRITISH JOURNAL OF DERMATOLOGY, 2018, 178 (05) :1083-1101
[8]   Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study [J].
Deleuran, Mette ;
Thaci, Diamant ;
Beck, Lisa A. ;
de Bruin-Weller, Marjolein ;
Blauvelt, Andrew ;
Forman, Seth ;
Bissonnette, Robert ;
Reich, Kristian ;
Soong, Weily ;
Hussain, Iftikhar ;
Foley, Peter ;
Hide, Michihiro ;
Bouaziz, Jean-David ;
Gelfand, Joel M. ;
Sher, Lawrence ;
Schuttelaar, Marie L. A. ;
Wang, Chen ;
Chen, Zhen ;
Akinlade, Bolanle ;
Gadkari, Abhijit ;
Eckert, Laurent ;
Davis, John D. ;
Rajadhyaksha, Manoj ;
Staudinger, Heribert ;
Graham, Neil M. H. ;
Pirozzi, Gianluca ;
Ardeleanu, Marius .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 82 (02) :377-388
[9]   Guidelines of care for the management of atopic dermatitis Section 1. Diagnosis and assessment of atopic dermatitis [J].
Eichenfield, Lawrence F. ;
Tom, Wynnis L. ;
Chamlin, Sarah L. ;
Feldman, Steven R. ;
Hanifin, Jon M. ;
Simpson, Eric L. ;
Berger, Timothy G. ;
Bergman, James N. ;
Cohen, David E. ;
Cooper, Kevin D. ;
Cordoro, Kelly M. ;
Davis, Dawn M. ;
Krol, Alfons ;
Margolis, David J. ;
Paller, Amy S. ;
Schwarzenberger, Kathryn ;
Silverman, Robert A. ;
Williams, Hywel C. ;
Elmets, Craig A. ;
Block, Julie ;
Harrod, Christopher G. ;
Begolka, Wendy Smith ;
Sidbury, Robert .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 70 (02) :338-351
[10]  
European Medicines Agency, DUPIXENT DUP SUMM PR